February 13, 2023 07:31 AM ESTUpdated 11:22 AM
Pharma

Up­dat­ed: Sor­ren­to files for Chap­ter 11 af­ter los­ing ar­bi­tra­tion to Patrick Soon-Sh­iong biotech

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sor­ren­to Ther­a­peu­tics is fil­ing for bank­rupt­cy fol­low­ing a years­long le­gal dis­pute.

The biotech sub­mit­ted its Chap­ter 11 pa­per­work Mon­day, per an

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times